Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Ramelteon
Takeda
Healthy
1 trial -
Rapid test for diagnosis orientation
Grace Therapeutics
Flu
1 trial -
Ready to Use Supplementary Food
United Therapeutics Europe Ltd
Moderate Acute Malnutrition
1 trial -
Ready-to-use school food
United Therapeutics Europe Ltd
School Attendance
1 trial -
Ready-to-use therapeutic food (RUTF)
United Therapeutics Europe Ltd
Severe Acute Malnutrition
1 trial -
Regional lymph node radiotherapy (RNI) including the axilla
The First People's Hospital of Lianyungang
Axillary Lymph Node Dissection
1 trial -
Regorafenib and Sintilimab in combination with electroacupuncture
The First People's Hospital of Lianyungang
Colorectal Cancer Metastatic
1 trial -
Rehabilitation Therapy as part of Standard of Care (Control)
BRIGHT MINDS BIOSCIENCES INC.
Acute Stroke
1 trial -
Remifentanil
Vera Therapeutics
Postoperative Pain
1 trial -
Remimazolam
The First People's Hospital of Lianyungang
Sedation and Analgesia
1 trial -
Remimazolam Tosilate
The First People's Hospital of Lianyungang
Frailty
1 trial -
Remimazolam besylate
The First People's Hospital of Lianyungang
Remimazolam
1 trial -
Remodulin
United Therapeutics Europe Ltd
Congenital Heart Disease
1 trial -
Respiratory monitoring
The First People's Hospital of Lianyungang
Post-Op Complication
1 trial -
Resveratrol, curcumin
Atrium Therapeutics
Effect of Resveratrol and Curcumin on Inflammation
1 trial -
Rifaximin
The First People's Hospital of Lianyungang
Bacterial Overgrowth Syndrome Small Bowel
1 trial -
Rifaximin
United Therapeutics Europe Ltd
Travelers' Diarrhea
1 trial -
Rifaximin
United Therapeutics Europe Ltd
Tropical Enteropathy
1 trial -
Rituximab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Peripheral T-Cell Lymphoma, Not Otherwise Specified
1 trial -
Rituximab, Methotrexate, and Thiotepa (R-MT) Induction Followed by Etoposide and Cytarabine (EA) Consolidation
The First People's Hospital of Lianyungang
Primary Central Nervous System Lymphoma (PCNSL)
1 trial -
Romiplostim N01
The First People's Hospital of Lianyungang
Primacy Immune Thrombocytopenia
1 trial -
Ropivacaine
The First People's Hospital of Lianyungang
Surgery
1 trial -
Routine Medication
The First People's Hospital of Lianyungang
Generalized Anxiety Disorder
1 trial -
Ruxolitinib+Calcineurin inhibitor+Methotrexate
The First People's Hospital of Lianyungang
Graft Versus Host Disease
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources